secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-07-13T23:59:59+00:00
Accession:  0001193125-22-192292
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines appoints Lorence Kim to Board, replacing Neil Exter
------------------------------------------------------------------------

- Dr. Kim appointed Class I director effective July 12, 2022, filling vacancy from Exter's resignation.
- Determined independent; qualifies as audit committee financial expert; served on Audit Committee.
- Venture Partner at Third Rock Ventures, former CFO of Moderna, and ex-Managing Director at Goldman Sachs.
- Received initial option for 36,800 shares and 10,500 RSUs under Non-Employee Director Compensation Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/0001193125-22-192292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522192292/d335098d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-192292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer